PFE · Earnings call · 2026Q3T · Full report

Products and Technology

PFIZER INC · 2026-11-03 · Importance 30 · Surprise 24

Pfizer is advancing atermaciclib as a potential next-generation treatment backbone in first-line and early HR-positive breast cancer, positioning its CDK4 selectivity against tolerability limitations of existing CDK4/6 inhibitors. In a Phase 2 study, atermaciclib plus fulvestrant reduced the risk of progression or death by 40% versus investigator’s choice in patients previously treated with a CDK4/6 inhibitor. Pfizer also reported cell-cycle arrest in 88% of participants’ tumors with atermaciclib plus letrozole in early breast cancer and plans a Phase 3 combination study with giredestrant.

Key facts

• Pfizer launched Genesis in more than 120 countries to reduce administrative work for safety scientists.